Purpose of Review <p>This review addresses recent advances in the pre- and post-transplant clinical course and treatment of patients with autoimmune hepatitis (AIH), as well as current insights on disease recurrence.</p> Recent Findings <p>Patients transplanted for AIH have generally good outcomes after transplant but are at higher risk of rejection, disease recurrence, and infection than non-autoimmune liver diseases. There is no standardized post-transplant immunosuppression approach for this population.</p> Summary <p>Immunosuppression following liver transplantation for AIH should balance graft survival with disease recurrence and rejection while minimizing adverse outcomes of long-term immunosuppression. Future research should aim to address knowledge gaps related to the prevention, early detection, and treatment of AIH recurrence in high-risk populations. Appropriate characterization of these patients is essential to optimize and tailor their post-transplant care.</p>